Milk Allergy Clinical Trials Market Report covers the manufacturer’s data, including: shipment, price,
revenue, gross profit, interview record, business distribution etc., these data help the consumer know
about the competitors better. This report also covers all the regions and countries of the world, which
shows a regional development status, including market size, volume and value, as well as price data.
The Global “Milk Allergy Clinical Trials Market” research 2019 highlights the major details and provides
in-depth analysis of the market along with the future growth, prospects and Industry demands analysis
explores with the help of complete report with 125 Pages, figures, graphs and table of contents to
analyze the situations of global Milk Allergy Clinical Trials Market and Assessment to 2023.
This report studies the Global Milk Allergy Clinical Trials Market over the forecast period of 2019 to
2023. The Global Milk Allergy Clinical Trials Market is expected to grow at an impressive Compound
Annual Growth Rate (CAGR) from 2019 to 2023.
According to the Report study, Cow’s milk allergy (CMA) is among the most common FA in early
childhood, with an estimated prevalence of 2% to 3%. The mission for Milk Allergy Clinical Trials is to
conduct basic and applied research to better understand, treat, and prevent infectious, immunologic,
and allergic diseases.
Milk Allergy Clinical Trials Market Covers the Table of Contents With Segments, Key Players And Region.
Based on Product Type, Milk Allergy Clinical Trials Market is sub segmented into Skin Prick Tests, Blood
Allergen Specific IgE Ttests, Oral Food Challenge, Food Elimination Diet. Based on application, the
market is sub segmented into Immediate Treatment and Management of CMPA.
Major Players profiled in the Milk Allergy Clinical Trials Market report incorporate: Dietary
Management Market Analysis, Mead Johnson, Danone SA, Perrigo Company, Abbott, Nestle,
FrieslandCampina
Industry News:
Mead Johnson is announce that a new independent study published online this week in the Journal of
Pediatrics shows significantly more infants with cow’s milk allergy who receive Nutramigen® LGG®, an
extensively hydrolyzed formula that includes Lactobacillus rhamnosus GG (LGG), built a tolerance to
cow’s milk compared to those fed other infant formulas used in the study.
Specifically, nearly four out of five (78.9 percent) infants fed Nutramigen LGG built a tolerance to cow’s
milk at 12 months, compared with infants fed other products* such as extensively hydrolyzed casein
formula (43.6 percent), rice hydrolyzed formula ( 32.6 percent), soy based formulas (23.6 percent) or
amino-acid based formulas (18.2 percent).
This is the first study to compare the impact of Nutramigen LGG to different formulas based on duration
of cow’s milk allergy in children. This study further builds upon the 70-year history of Nutramigen, which
has more breadth and depth of clinical trials than any other formula designed for cow’s milk allergy.